A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
Clinical trial NCT05039736 · WITHDRAWN
Trial details
- NCT number
- NCT05039736
- Sponsor
- M.D. Anderson Cancer Center
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-24
- Primary completion
- 2023-05-03
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.